STCube, Inc (052020) Fair Value & Analysis

Technology · KR · Market cap 498B KRW

Below-average quality, and screening another 91% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (1,063 KRW). The favourable scenario is already priced in.
• Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (561.37 KRW to 1,063 KRW) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.

How to read this chart

60‑month range 3,882 KRW – 23,439 KRW · fair‑value band 561.37 KRW – 1,063 KRW · the 9,230 KRW price screens above the 850.56 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

STCube, Inc (052020) currently trades at 9,230 KRW, while our model-based Fair Value estimate is 850.56 KRW, implying the stock looks roughly 90.8% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 6.5B KRW. Revenue declined 31.3% year over year. Fundamentals as of Jul 20, 2026

Our scenario range runs from 561.37 KRW (bear case) to 1,063 KRW (bull case); at 9,230 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 59% below its 52-week high and 44% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at 29% fair-value upside, at -91%, 052020 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea.

Full company description

STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a technology designed to screen for antibodies that selectively mask specific sites of target proteins; and Glyco-Specific Antibody Characterization and Optimization Platform, a technology designed to optimize characteristics exerted by antibodies that mask specific sites of target proteins. The company's product pipeline consists of various anti-cancer drugs, including programmed death ligand 1, a type of protein, which is expressed in cancer cells and interferes with the natural tumor killing of immune cells; programmed death-1, a type of protein that is expressed in T cells; and cytotoxic T-lymphocyte associated protein 4, a protein that inhibits the activity of T-cells that can kill cancer cells. Its product pipeline also comprises lymphocyte-activation gene 3, a type of protein, which exists in the cell membrane of immune cells, such as T-cells and NK cells. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. STCube, Inc. was founded in 1989 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

STCube, Inc reported revenue of 7.0B KRW in FY2025 versus 7.9B KRW in FY2021, a compound −3.1%/yr. Reported net income was −21.8B KRW in FY2025.

052020 screens 91% overvalued. Compare with VINATech Co →

Peer Group

Electronic Equipment & Parts · 21 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Electronic Equipment & Parts stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).

Explore undervalued stocks

More undervalued Technology stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.